STOCK TITAN

Cibus, Inc. Form 4 Filings

CBUS NASDAQ

Every Form 4 that Cibus, Inc. (CBUS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow CBUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBUS filings page.

Rhea-AI Summary

Cibus, Inc. CEO Craig Wichner reported new equity compensation awards. He received 894,309 shares of Class A Common Stock as a grant, with these restricted stock units vesting in four equal 25% installments on each of the first four anniversaries of the grant date.

He was also granted options covering 1,047,620 shares of Class A Common Stock at an exercise price of $1.23 per share. These options vest 25% per year over the first four anniversaries of the grant date and expire on June 8, 2036. All holdings reported are direct.

Rhea-AI Summary

Cibus, Inc. director Mark Terrence Finn reported receiving a grant of stock options. He was awarded 77,586 options to buy Class A common stock at an exercise price of $1.39 per share. The options vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual shareholder meeting, subject to his continued service. The options expire on June 2, 2036, and were granted as compensation rather than through any open-market transaction.

Rhea-AI Summary

Cibus, Inc. director August J. Moretti received a grant of 77,586 stock options on June 2, 2026 to buy Class A Common Stock at an exercise price of $1.39 per share. The options vest in full after one year or at the next annual shareholder meeting and expire on June 2, 2036.

Rhea-AI Summary

Cibus, Inc. director Rory B. Riggs reported receiving a grant of stock options. The award covers 77,586 options to buy Class A common stock at an exercise price of $1.39 per share, expiring on June 2, 2036.

According to the terms, these options vest in full, subject to his continued service, on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual meeting of shareholders. Following this grant, Riggs holds 77,586 derivative securities directly.

Rhea-AI Summary

Cibus, Inc. director Gerhard Prante reported an equity compensation grant involving the company’s Class A common stock. He acquired 64,748 shares at a stated price of $0.00 per share as a grant or award, rather than an open-market purchase. Following this award, his directly held position increased to 104,945 shares of Class A common stock.

The footnote explains that these are Restricted Stock Units that vest in full, subject to his continued service as a director, on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. This shows the grant is tied to ongoing board service rather than a discretionary market transaction.

Rhea-AI Summary

Lehmann Jean-Pierre Jules reported acquisition or exercise transactions in this Form 4 filing.

Cibus, Inc. director Jean-Pierre Jules Lehmann received an award of 64,748 shares of Class A Common Stock in the form of Restricted Stock Units. The award carries a price of $0.00 per share, indicating equity compensation rather than a market purchase. Following this grant, Lehmann directly holds 763,904 shares. The RSUs vest in full, subject to his continued service, on the earlier of one year from the grant date or the company’s next annual meeting of shareholders.

Rhea-AI Summary

Cibus, Inc. director Kimberly Ann Box received a grant of stock options on Class A Common Stock. The award covers 77,586 options with an exercise price of $1.39 per share and no upfront purchase cost. These options vest in full, subject to her continued service, on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual shareholder meeting, and expire on June 2, 2036. Following this grant, she holds 77,586 derivative securities directly through this option award.

Rhea-AI Summary

Cibus, Inc. director Craig Wichner received a grant of stock options covering 77,586 shares of Class A common stock. The options have an exercise price of $1.39 per share and expire on June 2, 2036.

According to the award terms, the options vest in full if the director continues to serve until the earlier of the first anniversary of the grant date or the company’s next annual meeting of shareholders. After this grant, Wichner holds 77,586 derivative securities tied to the company’s stock, reflecting routine equity-based director compensation rather than an open-market purchase or sale.

Rhea-AI Summary

Urban Thomas reported acquisition or exercise transactions in this Form 4 filing.

Cibus, Inc. director Urban Thomas received an equity award of 64,748 shares of Class A Common Stock at no purchase price, as reflected in a Form 4 insider filing. The award is in the form of Restricted Stock Units that vest in full, subject to his continued service, on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. Following this grant, Thomas is reported as directly holding 64,748 shares.

Rhea-AI Summary

Cibus, Inc. CFO Carlo Broos reported new equity compensation awards. He received 57,000 shares of Class A Common Stock at no purchase price and now holds 154,275 shares directly after this grant. He was also granted stock options for 114,000 shares of Class A Common Stock at an exercise price of $1.50 per share, expiring on April 24, 2036.

The options begin vesting on a monthly schedule, with 1/48th of the total options vesting on the 24th of each month until the fourth anniversary of the grant date. These are compensation-related acquisitions rather than open‑market purchases or sales.

Rhea-AI Summary

Cibus, Inc. director Urban Thomas received a grant of stock options as part of his compensation. On April 24, 2026, he was awarded options to acquire 9,094 shares of Class A common stock at an exercise price of $1.50 per share. The footnote states these options vest 100% on the grant date, so they are fully vested immediately. Following this grant, Thomas holds 9,094 stock options directly. This is a compensation-related award, not an open-market purchase or sale of Cibus shares.

Rhea-AI Summary

Cibus, Inc. reported that Sr VP, Research Noel Sauer received an equity compensation grant. Sauer acquired 38,000 shares of Class A Common Stock at $0.00 per share as an award, bringing direct holdings to 139,879 shares.

Sauer was also granted a stock option for 76,000 shares of Class A Common Stock at an exercise price of $1.50 per share, expiring on April 24, 2036. According to the footnote, 1/48th of the total options vest monthly on the 24th of each month until the fourth anniversary of the grant date.

Rhea-AI Summary

Cibus, Inc. granted Chief Administrative Officer, General Counsel and Corporate Secretary Jason Stokes 57,000 shares of Class A Common Stock as an equity award. He now directly holds 167,865 shares after this grant.

The company also awarded him a stock option for 114,000 shares of Class A Common Stock at an exercise price of $1.50 per share. According to the vesting terms, 1/48 of the options vest monthly on the 24th until the fourth anniversary of the grant date, and the options expire on April 24, 2036. These are compensation-related awards, not open-market purchases or sales.

Rhea-AI Summary

Cibus, Inc. reported that its CFO, Carlo Broos, received equity-based compensation. He was granted 57,000 shares of Class A Common Stock at no cost, bringing his direct holdings to 154,275 shares.

He was also granted 114,000 stock options to buy Class A Common Stock at an exercise price of $1.50 per share, exercisable starting on April 24, 2027 and expiring on April 24, 2036.

Rhea-AI Summary

Gocal Gregory Francis William reported acquisition or exercise transactions in this Form 4 filing.

Cibus, Inc. reported that Chief Scientific Officer & EVP Gregory Francis William Gocal received equity awards on April 24, 2026. He was granted 57,000 shares of Class A common stock and 114,000 stock options to buy Class A common at $1.50 per share.

Following the grant, he directly holds 422,890 common shares and 114,000 options. According to the vesting terms, 1/48th of the options vest monthly on the 24th of each month until the fourth anniversary of the grant date.

Rhea-AI Summary

Cibus, Inc. reported that Interim CEO, President and COO Peter Beetham received an equity compensation grant. He was awarded 195,000 shares of Class A common stock on April 24, 2026 at a price of $0.00 per share, bringing his direct holdings to 686,825 shares.

He also received a stock option for 390,000 shares of Class A common stock with an exercise price of $1.50 per share, exercisable until April 24, 2036. According to the vesting terms, 1/48th of the options vest monthly on the 24th of each month over four years from the grant date.

Rhea-AI Summary

Cibus, Inc. senior vice president of research Noel Sauer reported a routine tax-withholding disposition of 1,763 shares of Class A Common Stock on March 30, 2026. The shares were valued at a weighted average price of $1.84 per share. After this transaction, Sauer directly owns 101,879 shares of Cibus stock.

Rhea-AI Summary

Cibus, Inc. chief legal officer Jason Stokes reported a routine tax-related share disposition. On March 30, 2026, 3,695 shares of Class A Common Stock were withheld at a weighted average price of $1.83 per share to cover tax obligations. The withheld shares came from multiple trades priced between $1.81 and $1.88. After this transaction, Stokes directly held 110,865 shares of Cibus common stock.

Rhea-AI Summary

Cibus, Inc. CFO Broos Carlo reported a tax-related share disposition. On this Form 4, 3,676 shares of Class A Common Stock were disposed of at a weighted average price of $1.87 per share to satisfy tax obligations by delivering securities. After this transaction, Carlo directly holds 97,275 shares.

This was a tax-withholding disposition tied to equity compensation rather than an open-market trade, so it functions as an administrative event and does not reflect an active buy or sell decision on the open market.

Rhea-AI Summary

Cibus, Inc. Chief Scientific Officer and EVP Gregory Francis William Gocal reported a routine tax-withholding disposition of 8,954 shares of Class A Common Stock. The shares were applied at a weighted average price of $1.82 per share. After this transaction, he directly holds 365,890 shares of Cibus common stock.

Rhea-AI Summary

Cibus, Inc. director and interim CEO, president and COO Peter Beetham reported a tax-withholding disposition of 16,112 shares of Class A Common Stock on March 30, 2026. The weighted average price was $1.85 per share, with trades ranging from $1.81 to $2.10. Following this withholding to cover obligations, he directly holds 491,825 shares, indicating this was a routine compensation-related event rather than an open-market sale.

Rhea-AI Summary

Cibus, Inc. CFO Carlo Broos reported a small share disposition related to tax withholding. On this Form 4, 1,496 shares of Class A Common Stock were surrendered at $1.32 per share to cover tax obligations rather than sold on the open market. After this transaction, he directly holds 100,951 shares, so his overall ownership stake remains largely unchanged.

Rhea-AI Summary

Cibus, Inc. senior vice president of research Noel Sauer reported two transactions in Class A common stock. On November 11, 2025, 1,834 shares were disposed of at $1.32 per share as a tax-withholding transaction, rather than an open-market trade. Earlier, on June 13, 2025, Sauer completed a small open-market sale of 4 shares at $1.485 per share. Following these transactions, Sauer directly holds 103,642 shares of Cibus Class A common stock.

Rhea-AI Summary

Cibus, Inc. executive Jason Stokes, the company’s CLO, General Counsel and Secretary, reported routine share dispositions tied to tax obligations. Across three Form 4 entries using code F, a total of 13,109 Class A common shares were withheld to cover taxes, and he now holds 114,560 shares directly after the most recent transaction.

Rhea-AI Summary

Cibus, Inc. director Jean-Pierre Jules Lehmann reported buying 666,666 shares of Class A common stock at $1.50 per share in an underwritten public offering that closed on January 30, 2026. After the purchase, he directly owned 699,156 shares and was deemed to beneficially own an additional 1,687,071 shares held by JPL Investments, SA. The transaction was approved by Cibus, Inc.’s board of directors under Rule 16b-3.

Rhea-AI Summary

Cibus, Inc. director and 10% owner Rory B. Riggs purchased 333,333 shares of Class A Common Stock at $1.50 per share in a firm commitment underwritten public offering that closed on January 30, 2026. The purchase was approved by the board under Rule 16b-3. Following this transaction, he directly beneficially owned 14,916,640 shares, with additional indirect holdings of 23,807 shares held by the Rory Riggs Family Trust, where he is trustee with sole voting and dispositive power, and 20,974 shares held by his spouse.

Rhea-AI Summary

Cibus, Inc. (CBUS) reported an equity award to a company director. On 11/05/2025, the director received a stock option to buy 45,627 shares of Class A common stock at an exercise price of $1.32 per share. The option becomes exercisable on 05/22/2026 and expires on 11/05/2035, with no purchase price paid for the option itself. Following this grant, the director beneficially owns 45,627 derivative securities directly.

The option vests, subject to continued board service, on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting. Any remaining unvested portion will fully vest if a defined Triggering Event under the company’s 2017 Omnibus Incentive Plan occurs while the director continues to serve.

Rhea-AI Summary

Kimberly A. Box, a director of Cibus, Inc. (CBUS), was granted a stock option on 09/11/2025 to purchase 54,722 shares of Class A common stock at an exercise price of $1.40 per share. The option vests on the earlier of the first anniversary of the grant date or the company’s next annual shareholders meeting, subject to continued service, and becomes exercisable beginning 09/11/2026 with an expiration date of 09/11/2035. The filing reports direct beneficial ownership of 54,722 shares following the grant. The grant includes standard acceleration on a defined Triggering Event per the company’s 2017 Omnibus Incentive Plan.